Pipelines

© GettyImages/AndreyPopov

Disruptor in cell and gene therapy space secures US$30m in funding

By Jane Byrne

Ori Biotech Ltd (Ori), a London and New Jersey based innovator in the cell and gene therapy (CGT) manufacturing sphere, last week announced the successful close of a US$30m Series A financing round, bringing the company’s total funding to date to US$41m.

© GettyImages/YurolaitsAlbert

Lilly's COVID-19 antibody trial on hold over safety concerns

By Jane Byrne

Enrollment is temporarily on hold in the ACTIV-3 clinical trial, which is evaluating Lilly's investigational neutralizing antibody bamlanivimab (LY-CoV555) as a treatment for COVID-19 in hospitalized patients. The pause was recommended by the study's...

© GettyImages/iLexx

BARDA and Locus in tie-up to tackle UTIs with phages

By Jane Byrne

Locus Biosciences has signed a contract with BARDA to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage) that targets E. coli bacteria causing recurrent urinary tract infections (UTIs).

© GettyImages/solarseven

Cobra to supply plasmids to UK COVID-19 vaccine developer

By Jane Byrne

Contract development and manufacturing organization (CDMO), Cobra Biologics, has been selected to manufacture plasmids for a Phase I clinical trial of a COVID-19 vaccine being developed by UK company, Scancell.

Follow us

Products

View more

Webinars